Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 317,623Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercepharma.com/pharma/jj-bolsters-rybrevant-lazcluzes-case-against-azs-tagrisso-nominal-survival-win

FIERCE PHARMA
09 Sep 2024

https://www.globenewswire.com/news-release/2024/09/08/2942454/0/en/RYBREVANT-amivantamab-plus-lazertinib-show-strong-favourable-overall-survival-trend-versus-osimertinib-in-EGFR-mutated-advanced-lung-cancer.html

GLOBENEWSWIRE
08 Sep 2024

https://www.globenewswire.com/news-release/2024/08/30/2938443/0/en/LAZCLUZE-lazertinib-Now-Available-from-Onco360-for-the-First-line-Treatment-in-Combination-with-Rybrevant-of-Adult-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer-Whose-Tumors-.html

GLOBENEWSWIRE
30 Aug 2024
FDA Roundup: August 20, 2024
FDA Roundup: August 20, 2024

20 Aug 2024

// PR NEWSWIRE

https://www.prnewswire.com/news-releases/fda-roundup-august-20-2024-302226711.html

PR NEWSWIRE
20 Aug 2024

https://www.globenewswire.com/news-release/2024/06/03/2892527/0/en/Late-breaking-results-from-PALOMA-2-study-of-subcutaneous-RYBREVANT-amivantamab-in-combination-with-lazertinib-show-clinically-meaningful-antitumour-response-and-improved-safety-pr.html

GLOBENEWSWIRE
03 Jun 2024

https://www.prnewswire.com/news-releases/late-breaking-results-from-paloma-2-study-of-subcutaneous-amivantamab-in-combination-with-lazertinib-show-clinically-meaningful-antitumor-response-and-improved-safety-profile-in-patients-with-egfr-mutated-non-small-cell-lung-cance-302162281.html

PR NEWSWIRE
03 Jun 2024